发布求助
文献互助 智能选刊 最新文献

Trends in Endocrinology and Metabolism最新文献

筛选
英文 中文
Advanced microbiome therapeutics as a novel modality for oral delivery of peptides to manage metabolic diseases. 先进的微生物组疗法是口服多肽治疗代谢性疾病的一种新方法。
IF 10.9 1区 医学
Trends in Endocrinology and Metabolism Pub Date : 2024-05-22 DOI: 10.1016/j.tem.2024.04.021
Ruben Vazquez-Uribe, Karl Alex Hedin, Tine Rask Licht, Max Nieuwdorp, Morten O A Sommer
{"title":"Advanced microbiome therapeutics as a novel modality for oral delivery of peptides to manage metabolic diseases.","authors":"Ruben Vazquez-Uribe, Karl Alex Hedin, Tine Rask Licht, Max Nieuwdorp, Morten O A Sommer","doi":"10.1016/j.tem.2024.04.021","DOIUrl":"https://doi.org/10.1016/j.tem.2024.04.021","url":null,"abstract":"<p><p>The rising prevalence of metabolic diseases calls for innovative treatments. Peptide-based drugs have transformed the management of conditions such as obesity and type 2 diabetes. Yet, challenges persist in oral delivery of these peptides. This review explores the potential of 'advanced microbiome therapeutics' (AMTs), which involve engineered microbes for delivery of peptides in situ, thereby enhancing their bioavailability. Preclinical work on AMTs has shown promise in treating animal models of metabolic diseases, including obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease. Outstanding challenges toward realizing the potential of AMTs involve improving peptide expression, ensuring predictable colonization control, enhancing stability, and managing safety and biocontainment concerns. Still, AMTs have potential for revolutionizing the treatment of metabolic diseases, potentially offering dynamic and personalized novel therapeutic approaches.</p>","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141088614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Why cells need iron: a compendium of iron utilisation. 细胞为什么需要铁：铁利用简编》。
IF 10.9 1区 医学
Trends in Endocrinology and Metabolism Pub Date : 2024-05-16 DOI: 10.1016/j.tem.2024.04.015
Megan R Teh, Andrew E Armitage, Hal Drakesmith
{"title":"Why cells need iron: a compendium of iron utilisation.","authors":"Megan R Teh, Andrew E Armitage, Hal Drakesmith","doi":"10.1016/j.tem.2024.04.015","DOIUrl":"https://doi.org/10.1016/j.tem.2024.04.015","url":null,"abstract":"<p><p>Iron deficiency is globally prevalent, causing an array of developmental, haematological, immunological, neurological, and cardiometabolic impairments, and is associated with symptoms ranging from chronic fatigue to hair loss. Within cells, iron is utilised in a variety of ways by hundreds of different proteins. Here, we review links between molecular activities regulated by iron and the pathophysiological effects of iron deficiency. We identify specific enzyme groups, biochemical pathways, cellular functions, and cell lineages that are particularly iron dependent. We provide examples of how iron deprivation influences multiple key systems and tissues, including immunity, hormone synthesis, and cholesterol metabolism. We propose that greater mechanistic understanding of how cellular iron influences physiological processes may lead to new therapeutic opportunities across a range of diseases.</p>","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140960889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical potential of fasting in type 1 diabetes. 1 型糖尿病患者禁食的临床潜力。
IF 11.4 1区 医学
Trends in Endocrinology and Metabolism Pub Date : 2024-05-01 Epub Date: 2024-02-07 DOI: 10.1016/j.tem.2024.01.007
Krista A Varady, Mary-Claire Runchey, Sirimon Reutrakul, Alaina P Vidmar, Lisa S Chow
{"title":"Clinical potential of fasting in type 1 diabetes.","authors":"Krista A Varady, Mary-Claire Runchey, Sirimon Reutrakul, Alaina P Vidmar, Lisa S Chow","doi":"10.1016/j.tem.2024.01.007","DOIUrl":"10.1016/j.tem.2024.01.007","url":null,"abstract":"<p><p>Most adults with type 1 diabetes (T1DM) are either overweight or obese. As such, dietary management is recommended as an adjunct to insulin treatment to improve glycemic control and facilitate weight loss in these patients. Time-restricted eating (TRE) is a form of intermittent fasting that offers a simplified approach to treating obesity in T1DM. TRE typically involves restricting eating to 6 to 10 h per day, with water and medications allowed outside the eating window. This review examines the efficacy of TRE and other fasting protocols in improving weight and glycemic control in patients with obesity and T1DM. This review will also evaluate the safety of these regimens and provide advice to clinicians on implementing intermittent fasting in T1DM.</p>","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":"413-424"},"PeriodicalIF":11.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139708593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors. 钠-葡萄糖共转运体-2 抑制剂的全身和器官特异性抗炎作用。
IF 11.4 1区 医学
Trends in Endocrinology and Metabolism Pub Date : 2024-05-01 Epub Date: 2024-02-29 DOI: 10.1016/j.tem.2024.02.003
Mona Mashayekhi, Bilgunay Ilkin Safa, Matthew S C Gonzalez, Sangwon F Kim, Justin B Echouffo-Tcheugui
{"title":"Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors.","authors":"Mona Mashayekhi, Bilgunay Ilkin Safa, Matthew S C Gonzalez, Sangwon F Kim, Justin B Echouffo-Tcheugui","doi":"10.1016/j.tem.2024.02.003","DOIUrl":"10.1016/j.tem.2024.02.003","url":null,"abstract":"<p><p>Inflammation plays an essential role and is a common feature in the pathogenesis of many chronic diseases. The exact mechanisms through which sodium-glucose cotransporter-2 (SGLT2) inhibitors achieve their much-acclaimed clinical benefits largely remain unknown. In this review, we detail the systemic and tissue- or organ-specific anti-inflammatory effects of SGLT2 inhibitors using evidence from animal and human studies. We discuss the potential pathways through which SGLT2 inhibitors exert their anti-inflammatory effects, including oxidative stress, mitochondrial, and inflammasome pathways. Finally, we highlight the need for further investigation of the extent of the contribution of the anti-inflammatory effects of SGLT2 inhibition to improvements in cardiometabolic and renal outcomes in clinical studies.</p>","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":"425-438"},"PeriodicalIF":11.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11096060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139998315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitochondrial dysfunction in lipid processing and gastrointestinal disorders. 线粒体在脂质处理和胃肠道疾病中的功能障碍。
IF 11.4 1区 医学
Trends in Endocrinology and Metabolism Pub Date : 2024-05-01 Epub Date: 2024-02-27 DOI: 10.1016/j.tem.2024.02.009
Yan Hu, Hao Huang, Rong Xiang
{"title":"Mitochondrial dysfunction in lipid processing and gastrointestinal disorders.","authors":"Yan Hu, Hao Huang, Rong Xiang","doi":"10.1016/j.tem.2024.02.009","DOIUrl":"10.1016/j.tem.2024.02.009","url":null,"abstract":"<p><p>Mitochondrial dysfunctions predominantly cause encephalomyopathies with muscle atrophy and neurodegeneration. However, their impact on other tissues, particularly the gastrointestinal tract, requires further investigation. In a recent report in Nature, Moschandrea et al. used mice deficient in the mitochondrial aminoacyl-tRNA synthetase DARS2 to investigate the role of enterocytic mitochondria in dietary lipid processing and transport. Their work sheds light on the development of gastrointestinal disorders as a result of mitochondrial dysfunction.</p>","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":"364-366"},"PeriodicalIF":11.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139991811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current status and future perspectives of FGF21 analogues in clinical trials. FGF21 类似物在临床试验中的现状和未来展望。
IF 11.4 1区 医学
Trends in Endocrinology and Metabolism Pub Date : 2024-05-01 Epub Date: 2024-02-28 DOI: 10.1016/j.tem.2024.02.001
Zara Siu Wa Chui, Qing Shen, Aimin Xu
{"title":"Current status and future perspectives of FGF21 analogues in clinical trials.","authors":"Zara Siu Wa Chui, Qing Shen, Aimin Xu","doi":"10.1016/j.tem.2024.02.001","DOIUrl":"10.1016/j.tem.2024.02.001","url":null,"abstract":"<p><p>Recent advances in fibroblast growth factor 21 (FGF21) biology and pharmacology have led to the development of several long-acting FGF21 analogues and antibody-based mimetics now in various phases of clinical trials for the treatment of obesity-related metabolic comorbidities. The efficacy of these FGF21 analogues/mimetics on glycaemic control and weight loss is rather mild and inconsistent; nevertheless, several promising therapeutic benefits have been reproducibly observed in most clinical studies, including amelioration of dyslipidaemia (particularly hypertriglyceridaemia) and hepatic steatosis, reduction of biomarkers of liver fibrosis and injury, and resolution of metabolic dysfunction-associated steatohepatitis (MASH). Evidence is emerging that combination therapy with FGF21 analogues and other hormones (such as glucagon-like peptide 1; GLP-1) can synergise their pharmacological benefits, thus maximising the therapeutic efficacy for obesity and its comorbidities.</p>","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":"371-384"},"PeriodicalIF":11.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139998313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nucleosides are overlooked fuels in central carbon metabolism. 核苷是被忽视的碳代谢中心燃料。
IF 10.9 1区 医学
Trends in Endocrinology and Metabolism Pub Date : 2024-04-01 Epub Date: 2024-02-29 DOI: 10.1016/j.tem.2024.01.013
Abigail Strefeler, Joan Blanco-Fernandez, Alexis A Jourdain
{"title":"Nucleosides are overlooked fuels in central carbon metabolism.","authors":"Abigail Strefeler, Joan Blanco-Fernandez, Alexis A Jourdain","doi":"10.1016/j.tem.2024.01.013","DOIUrl":"10.1016/j.tem.2024.01.013","url":null,"abstract":"<p><p>From our daily nutrition and synthesis within cells, nucleosides enter the bloodstream and circulate throughout the body and tissues. Nucleosides and nucleotides are classically viewed as precursors of nucleic acids, but recently they have emerged as a novel energy source for central carbon metabolism. Through catabolism by nucleoside phosphorylases, the ribose sugar group is released and can provide substrates for lower steps in glycolysis. In environments with limited glucose, such as at sites of infection or in the tumor microenvironment (TME), cells can use, and may even require, this alternative energy source. Here, we discuss the implications of these new findings in health and disease and speculate on the potential new roles of nucleosides and nucleic acids in energy metabolism.</p>","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":"290-299"},"PeriodicalIF":10.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139998314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Context matters for addressing controversies in FGF21 biology. 解决 FGF21 生物学争议的背景很重要。
IF 10.9 1区 医学
Trends in Endocrinology and Metabolism Pub Date : 2024-04-01 Epub Date: 2024-03-01 DOI: 10.1016/j.tem.2024.02.013
Chih-Ting Wu, Karen K Ryan
{"title":"Context matters for addressing controversies in FGF21 biology.","authors":"Chih-Ting Wu, Karen K Ryan","doi":"10.1016/j.tem.2024.02.013","DOIUrl":"10.1016/j.tem.2024.02.013","url":null,"abstract":"<p><p>Recent discoveries by Solon-Biet and colleagues highlight the importance of nutritional context for addressing current controversies in Fibroblast Growth Factor 21 (FGF21) biology. Through a series of complex studies, the authors explored the physiological and pharmacological effects of FGF21 on feeding behavior and energy balance under differing nutritional and metabolic statuses.</p>","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":"280-281"},"PeriodicalIF":10.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140023344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The landscape of fetus metabolism in maternal hyperglycemia. 母体高血糖时胎儿的新陈代谢状况。
IF 10.9 1区 医学
Trends in Endocrinology and Metabolism Pub Date : 2024-04-01 Epub Date: 2024-02-09 DOI: 10.1016/j.tem.2024.01.012
Miranda E Kelly, Thomas F Martinez, Cholsoon Jang
{"title":"The landscape of fetus metabolism in maternal hyperglycemia.","authors":"Miranda E Kelly, Thomas F Martinez, Cholsoon Jang","doi":"10.1016/j.tem.2024.01.012","DOIUrl":"10.1016/j.tem.2024.01.012","url":null,"abstract":"<p><p>Maternal hyperglycemia contributes to abnormal fetal development; yet, how it affects fetal metabolism is poorly understood. Perez-Ramirez and colleagues recently provided a comprehensive metabolic atlas of fetal organs isolated from normal and diabetic pregnant mice, identifying novel metabolites and alterations in tissue glucose utilization throughout mid-to-late gestation by maternal hyperglycemia.</p>","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":"282-284"},"PeriodicalIF":10.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11070186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139716671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regulated cell death in myocardial ischemia-reperfusion injury. 心肌缺血再灌注损伤中细胞死亡的调控。
IF 10.9 1区 医学
Trends in Endocrinology and Metabolism Pub Date : 2024-03-01 Epub Date: 2023-11-17 DOI: 10.1016/j.tem.2023.10.010
Qi Xiang, Xin Yi, Xue-Hai Zhu, Xiang Wei, Ding-Sheng Jiang
{"title":"Regulated cell death in myocardial ischemia-reperfusion injury.","authors":"Qi Xiang, Xin Yi, Xue-Hai Zhu, Xiang Wei, Ding-Sheng Jiang","doi":"10.1016/j.tem.2023.10.010","DOIUrl":"10.1016/j.tem.2023.10.010","url":null,"abstract":"<p><p>Myocardial ischemia-reperfusion (I/R) injury most commonly occurs in coronary artery disease when prompt reperfusion is used to salvage the ischemic myocardium. Cardiomyocyte death is a significant component of myocardial I/R injury and its mechanism was previously thought to be limited to apoptosis and necrosis. With the discovery of novel types of cell death, ferroptosis, necroptosis, and pyroptosis have been shown to be involved in myocardial I/R. These new forms of regulated cell death cause cardiomyocyte loss and exacerbate I/R injury by affecting reactive oxygen species (ROS) generation, calcium stress, and inflammatory cascades, subsequently mediating adverse remodeling, cardiac dysfunction, and heart failure. Herein, we review the roles of ferroptosis, necroptosis, and pyroptosis in myocardial I/R and discuss their contribution to pathology.</p>","PeriodicalId":54415,"journal":{"name":"Trends in Endocrinology and Metabolism","volume":" ","pages":"219-234"},"PeriodicalIF":10.9,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138048806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信